Medical research

Why some cancers may respond poorly to key drugs discovered

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of ...

Oncology & Cancer

A new way to target cancers using 'synthetic lethality'

With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the ...

Oncology & Cancer

Cancer researchers locate drivers of tumor resistance

Cancer biologists at the Mays Cancer Center, home to UT Health San Antonio MD Anderson, have identified important drivers that enable tumors to change their behavior and evade anticancer therapies.

page 15 from 40